Clinical Trials and Evidence-Based Medicine – Randomised Controlled Trials, Systematic Reviews

Definition and Core Concept

This article defines Clinical Trials as prospective research studies in which human participants are assigned to interventions (or no intervention) according to a protocol to evaluate the effects on health outcomes. Randomised controlled trials (RCTs) are the gold standard for evaluating interventions because randomisation balances known and unknown confounding factors. Evidence-based medicine (EBM) is the systematic approach to clinical decision-making that integrates the best available research evidence with clinical expertise and patient values. Core features: (1) phases of clinical trials (Phase I: safety and dosing in small groups; Phase II: efficacy and side effects; Phase III: large-scale comparative effectiveness; Phase IV: post-marketing surveillance), (2) randomisation methods (simple, block, stratified, adaptive, cluster), (3) blinding (masking) (single-blind, double-blind, triple-blind to reduce bias), (4) systematic reviews and meta-analyses (comprehensive synthesis of all studies on a question, with or without statistical pooling), (5) evidence grading frameworks (GRADE – Grading of Recommendations Assessment, Development and Evaluation). The article addresses: stated objectives of clinical trials and EBM; key concepts including intention-to-treat analysis, surrogate endpoints, subgroup analysis, and publication bias; core mechanisms such as trial registration (ClinicalTrials.gov), data monitoring committees, and CONSORT reporting guidelines; international comparisons and debated issues (generalisability of trial results, placebo use, pragmatic vs explanatory trials); summary and emerging trends (platform trials, adaptive designs, real-world evidence integration); and a Q&A section.

1. Specific Aims of This Article

This article describes clinical trials and evidence-based medicine without endorsing specific interventions. Objectives commonly cited: determining whether new or existing interventions are safe and effective, comparing the effectiveness of alternative treatment strategies, quantifying the magnitude of benefit and risk, and informing clinical guidelines and policy. The article notes that RCTs are resource-intensive (average Phase III trial costs $20-50 million), take years to complete, and may not fully represent real-world patient populations.

2. Foundational Conceptual Explanations

Key terminology:

• Randomised controlled trial (RCT): Study in which participants are assigned by chance (randomly) to intervention or control (placebo, usual care, or alternative intervention) groups. Randomisation minimises selection bias and confounding.
• Intention-to-treat (ITT) analysis: Analysing participants in the groups to which they were originally randomised, regardless of whether they completed or adhered to the assigned intervention. Preserves the benefits of randomisation and reflects real-world effectiveness.
• Per-protocol analysis (on-treatment): Analysing only participants who completed the intervention as assigned. May estimate efficacy (ideal conditions) but introduces selection bias.
• Primary outcome (endpoint): The main outcome measured to answer the research question (e.g., mortality, disease progression, symptom score). Secondary outcomes provide additional information.
• Surrogate endpoint: A laboratory measurement (e.g., blood pressure, cholesterol, tumour shrinkage) used as a substitute for a clinical outcome (e.g., heart attack, deaths). Surrogate validation requires evidence that change in surrogate reliably predicts change in clinical outcome.
• Number needed to treat (NNT): Number of patients needed to treat with an intervention to prevent one additional adverse outcome (or achieve one additional benefit). NNT = 1 / absolute risk reduction. Lower NNT indicates more effective intervention.

Phases of clinical trials (US FDA / EMA framework):

• Phase I: 20-100 healthy volunteers or patients; assess safety, tolerability, pharmacokinetics, pharmacodynamics; determine dose range. Duration months.
• Phase II: 100-500 patients with the condition; assess preliminary efficacy (proof-of-concept), optimal dosing, and further safety. Duration months to 2 years.
• Phase III (pivotal): 300-3,000+ patients; large-scale randomised trial to confirm efficacy, monitor adverse events, compare to standard treatment; required for regulatory approval. Duration 1-4 years.
• Phase IV (post-marketing): thousands to tens of thousands of patients after approval; monitor long-term safety (rare adverse events), effectiveness in real-world populations, comparisons with other treatments.

3. Core Mechanisms and In-Depth Elaboration

Randomisation methods:

• Simple randomisation (coin flip, random number generator) – equivalent groups in expectation, but chance imbalance possible in small samples.
• Block randomisation (permuted blocks of fixed size, e.g., 4 participants: 2 to intervention, 2 to control) – ensures balance over time.
• Stratified randomisation – randomises separately within strata (e.g., age group, disease severity) to ensure baseline balance for important prognostic factors.
• Minimisation (dynamic allocation) – algorithmally assigns next participant to treatment group that minimises imbalance across multiple factors.

Blinding (masking) procedures:

• Single-blind: either participant or investigator (but not both) unaware of assignment.
• Double-blind: both participant and investigator (including outcome assessors) unaware of assignment.
• Triple-blind: participant, investigator, and data analyst unaware.
• Placebo-controlled: control group receives inert substance indistinguishable from active intervention (to blind participants).
• Active-controlled: control group receives standard treatment (for conditions where placebo would be unethical).

Systematic review and meta-analysis:

• Systematic review: comprehensive literature search (multiple databases, grey literature) using explicit search strategy, inclusion/exclusion criteria, risk of bias assessment (Cochrane RoB tool), and qualitative synthesis.
• Meta-analysis: statistical pooling of effect estimates from multiple studies, using fixed-effect (assumes all studies estimate same true effect) or random-effects (allows between-study variation) models. Results presented as forest plot with overall effect estimate and prediction interval.
• Heterogeneity assessment: I² statistic (percentage of total variation across studies due to heterogeneity rather than chance). I² > 75% indicates substantial heterogeneity, requiring exploration (subgroup analysis, meta-regression).

GRADE (Grading of Recommendations, Assessment, Development and Evaluation):

• Evidence quality rated as high, moderate, low, or very low based on: study design (RCTs start high, observational studies low), risk of bias, inconsistency, indirectness, imprecision, publication bias.
• Recommendations: strong (or weak/conditional), based on evidence quality, balance of benefits and harms, patient values, resource use.

Reporting guidelines (EQUATOR Network):

• CONSORT (Consolidated Standards of Reporting Trials) for RCTs.
• PRISMA for systematic reviews and meta-analyses.
• STROBE for observational studies.

Effectiveness evidence (on EBM principles):

• Systematic review of clinical trial registration (early 2000s): Non-publication of negative trials (publication bias) inflated apparent treatment effects by 15-30%. Mandatory registration (ClinicalTrials.gov 2007, WHO ICTRP 2005) reduced but did not eliminate publication bias.
• Risk of bias assessments: Many published trials have methodological limitations (lack of blinding, incomplete outcome data, selective reporting) that moderate estimated treatment effects (by 10-40%) compared to high-quality trials.

4. Comprehensive Overview and Objective Discussion

International clinical trial oversight:

Debated issues:

1. Generalisability of trial results (external validity): RCT inclusion/exclusion criteria often restrict participants to healthier, younger, less comorbid populations than real-world patients. Efficacy (trial results) may differ from effectiveness (real-world performance). Pragmatic trials (broad inclusion criteria) address this gap.
2. Placebo use – ethical considerations: Placebo-controlled trials are ethical when no proven therapy exists or when proven therapy has high side effect profile and placebo poses low risk. When proven therapy exists, placebo control may deny effective treatment. Active-controlled (non-inferiority) trials are alternatives.
3. Selective outcome reporting and trial registration compliance: Despite mandates, many trials (estimated 20-30% of registered trials) do not post results or report primary outcomes changed from registration. Amendments must be documented.
4. Industry sponsorship and bias: Meta-analyses show industry-sponsored trials are more likely to report positive results for the sponsor’s product than non-industry-sponsored trials (odds ratio 2-4). Mechanisms: choice of comparator, selective reporting, publication bias, ghostwriting. Full transparency (data sharing, registration, conflict-of-interest disclosure) mitigates but does not eliminate.

5. Summary and Future Trajectories

Summary: Clinical trials (Phase I-IV, with RCTs for comparative efficacy) use randomisation and blinding to reduce bias. Intention-to-treat analysis preserves randomisation. Systematic reviews and meta-analyses synthesise evidence from multiple trials. GRADE rates evidence quality and recommendation strength. Trials have generalisability limitations; pragmatic trials improve real-world relevance.

Emerging trends:

• Platform trials: Master protocol evaluating multiple interventions simultaneously (within a single disease area), with arms added or dropped as evidence accumulates (e.g., REMAP-CAP, RECOVERY for certain infectious conditions). Increases efficiency, reduces sample size.
• Adaptive trial designs: Pre‑planned modifications (sample size re-estimation, dropping ineffective arms, enrichment) based on interim data, while preserving type I error. Requires robust statistical methods and trial conduct infrastructure.
• Real-world evidence (RWE) integration with RCTs: External control arms (using historical or real-world data to supplement or replace placebo groups), and trial emulation using electronic health records.
• Patient engagement and patient-reported outcomes (PROs): Including patients in trial design, patient-important outcomes (not just biomarkers, but function, quality of life), and direct patient reporting.

6. Question-and-Answer Session

Q1: What is the difference between efficacy and effectiveness in clinical trials?
A: Efficacy (explanatory trial) measures whether an intervention produces a positive result under ideal conditions (high adherence, narrow patient selection, protocol adherence). Effectiveness (pragmatic trial) measures whether it works in routine clinical practice (broader inclusion, less intensive follow-up, typical adherence). Both are important for regulatory approval and clinical guidelines.

Q2: Are all randomised controlled trials double-blind?
A: No. Many trials cannot be double-blinded because the intervention is obvious (surgery, exercise, device). Single-blind (participant unaware) or open-label (no masking) designs are used, with outcome assessors blinded to allocation to reduce detection bias.

Q3: What is a meta-analysis and when is it appropriate?
A: A meta-analysis is a statistical synthesis of results from separate but similar studies. Appropriate when studies are sufficiently homogeneous in design, population, intervention, and outcome to justify pooling. Assess heterogeneity (I²) and conduct subgroup analyses to explore differences.

Q4: How is evidence quality downgraded in GRADE?
A: For RCTs, start as high quality. Downgrade for: risk of bias (serious limitations in trial conduct), inconsistency (unexplained heterogeneity in results), indirectness (differences in population, intervention, comparator, outcome), imprecision (wide confidence intervals, few events), and publication bias (suspicion that negative trials not published).

https://clinicaltrials.gov/
https://www.who.int/clinical-trials-registry-platform
https://www.gradeworkinggroup.org/
https://www.consort-statement.org